Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival

Virchows Archiv

Volumn 448, Issue 1, 2006, Pages 35-45

  Mondada, David ^a   Bosman, Fredrik T ^a   Fontolliet, Charlotte ^a   Seelentag, Walter K F ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Antibodies; Carcinoma; Hepatocellular; Immunohistochemistry; Monoclonal; Prognosis

Indexed keywords

BIOCHEMICAL MARKER; HEPATOCYTE PARAFFIN 1 ANTIBODY; MEMBRANE METALLOENDOPEPTIDASE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEPRILYSIN; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 31744444668     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-005-0081-5     Document Type: Article

References (40)

1. Adachi E, Maeda T, Kajiyama K, Kinukawa N, Matsumata T, Sugimachi K, Tsuneyoshi M (1996) Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Cancer 77:2022-2031
2. Anthony PP (2001) Hepatocellular carcinoma: an overview. Histopathology 39:109-118
3. Armitage P, Berry G, Matthews JNS (1987) Statistical methods in medical research, 2nd edn. Blackwell, Oxford
4. Bene MC, Faure GC (1997) CD10 in acute leukemias. GEIL (Groupe d'Etude Immunologique des Leucemies). Haematologica 82:205-210
5. Borscheri N, Roessner A, Rocken C (2001) Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am J Surg Pathol 25:1297-1303
6. Christensen E (1987) Multivariate survival analysis using Cox's regression model. Hepatology 7:1346-1358
7. Chu P, Arber DA (2000) Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 113:374-382
8. Chu PG, Ishizawa S, Wu E, Weiss LM (2002) Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 26:978-988
9. Colombo M (1992) Hepatocellular carcinoma. J Hepatol 15:225-236
10. Cox D (1972) Regession models and life tables. J R Stat Soc B 34:187-220
11. Dragovic T, Deddish PA, Tan F, Weber G, Erdos EG (1994) Increased expression of neprilysin (neutral endopeptidase 24.11) in rat and human hepatocellular carcinomas. Lab Invest 70: 107-113
12. Dragovic T, Sekosan M, Becker RP, Erdos EG (1997) Detection of neutral endopeptidase 24.11 (neprilysin) in human hepatocellular carcinomas by immunocytochemistry. Anticancer Res 17: 3233-3238
13. Edmondson H, Steiner P (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462-503
14. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750
15. Greenwood M (1926) Reports on public health and medical subjects: the natural duration of cancer. HMSO 33:1-16
16. Hamilton SR, Aaltonen LA (eds) (2000) Pathology and genetics of tumors of the digestive system. IARC Press, Lyon
17. Hanazaki K, Kajikawa S, Koide N, Adachi W, Amano J (2001) Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 96:1243-1250
18. Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, Shimazaki J, Yoshimi F, Fukao K (2002) Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 8:450-456
19. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
20. Kobayashi T, Sugawara Y, Shi YZ, Makuuchi M (2002) Telomerase expression and p53 status in hepatocellular carcinoma. Am J Gastroenterol 97:3166-3171
21. Kumagai I, Masuda T, Sato S, Ishikawa K (2001) Immunoreactivity to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to histopathological grade and histological pattern. Hepatol Res 20:312-319
22. Lamps LW, Folpe AL (2003) The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review. Adv Anat Pathol 10:39-43
23. Lauwers GY, Terris B, Balis UJ, Batts KP, Regimbeau JM, Chang Y, Graeme-Cook F, Yamabe H, Ikai I, Cleary KR, Fujita S, Flejou JF, Zukerberg LR, Nagorney DM, Belghiti J, Yamaoka Y, Vauthey JN (2002) Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 26:25-34
24. Lauwers GY, Vauthey JN (1998) Pathological aspects of hepatocellular carcinoma: a critical review of prognostic factors. Hepatogastroenterology 45:1197-1202
25. Leong AS, Sormunen RT, Tsui WM, Liew CT (1998) Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology 33:318-324
26. Medina-Franco H, Sellers MT, Eckhoff DE, Bynon JS, Urist MM, Heslin MJ (2001) Multimodality treatment for patients with hepatocellular carcinoma: analysis of prognostic factors in a single Western institution series. J Gastrointest Surg 5:638-645
27. Minervini MI, Demetris AJ, Lee RG, Carr BI, Madariaga J, Nalesnik MA (1997) Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 10:686-692
28. Morrison C, Marsh W Jr, Frankel WL (2002) A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol 15:1279-1287
29. Nzeako UC, Goodman ZD, Ishak KG (1996) Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinicohistopathologic study of 804 North American patients. Am J Clin Pathol 105:65-75
30. Okuda K (2002) Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 17:401-405
31. Sato Y, Itoh F, Hareyama M, Satoh M, Hinoda Y, Seto M, Ueda R, Imai K (1999) Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma. J Gastroenterol 34:486-493
32. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A (2001) Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 48:103-109
33. Sezaki N, Ishimaru F, Tabayashi T, Kataoka I, Nakase K, Fujii K, Kozuka T, Nakayama H, Harada M, Tanimoto M (2003) The type 1 CD10/neutral endopeptidase 24.11 promoter: functional characterization of the 5′-untranslated region. Br J Haematol 123:177-183
34. Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumors. Wiley, New York
35. Thiery JP, Humbert P, Russell S, Richardson H (2002) Epithelial- mesenchymal transitions in tumour progression Dig, Scribble and Lgl in cell polarity, cell proliferation and cancer. Nat Rev Cancer 2:442-454
36. Turner AJ, Isaac RE, Coates D (2001) The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23:261-269
37. Turner AJ, Tanzawa K (1997) Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. Faseb J 11:355-364
38. Wennerberg AE, Nalesnik MA, Coleman WB (1993) Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol 143:1050-1054
39. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY (1996) Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol 149:1167-1175
40. Xiao SY, Wang HL, Hart J, Fleming D, Beard MR (2001) cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma. Am J Pathol 159:1415-1421